Resources
13 Results (showing 1 - 10)
Results sorted by posted date (oldest first)
Results sorted by posted date (oldest first)
Posted 6/26/2020 (updated 3/28/2024)
This brief, made possible by the Centers for Medicare & Medicaid Services, highlights key features of approved health home models in Maryland, Rhode Island, and Vermont that are tailored to individuals with opioid dependency.
Posted 3/25/2021 (updated 4/5/2024)
Documentation, Coding, and Billing for SUD/OUD via Medication-Assisted Treatment (MAT): A Rural and Community Health Focus
The presenter will outline the steps needed to effectively document, code, and bill for services including screening for SUD/OUD and providing care during the induction, stabilization, and maintenance phases of MAT. Individual state Medicaid issues are too numerous and will not be specifically referred to on a state-by-state basis.
Posted 5/10/2021 (updated 4/10/2024)
Participants will be provided an overview on how to appropriately document, code and bill for encounters throughout the SUD/OUD continuum of care following CMS billing rules for FQHCs/RHC. An overview of the opportunities and challenges associated with MAT reimbursement mechanisms including coding and billing for Medicare, managed care, Medicaid, and other third-party payors will also be presented as will a brief description of revenue options for reporting Transitional Care Management, Virtual Communication Services, Telehealth, and other care management services such as Behavioral Health Integration and the Psychiatric Collaborative Care Model.
Posted 10/14/2021 (updated 4/3/2024)
Stimulant intoxication, withdrawal, and psychosis have accepted and established treatment strategies. Several lifesaving harm reduction interventions/services are available. There are no Food and Drug Administration-approved medications for treatment of stimulant use disorder, although several are promising. Behavioral treatment, especially the use of contingency management (and other approaches with supportive evidence), has by far the best evidence of effectiveness. The presenter reviewed topics of importance to clinicians treating individuals with stimulant use disorder.
Rick Rawson, PhD, University of Vermont Rural Center of Excellence
Posted 12/20/2022 (updated 3/27/2024)
The Centers for Medicare & Medicaid Services (CMS) recently released the Calendar Year (CY) 2023 Physician Fee Schedule. This rule makes policy updates which may increase accessibility of behavioral health services and telehealth services in rural areas. CMS subject matter experts from the Hospital and Ambulatory Policy Group (HAPG) presented on the behavioral health and telehealth updates in the rule during the webinar held on Wednesday, December 14, 2022.
Posted 2/28/2023 (updated 3/27/2024)
In November 2022, the FDA issued a letter providing information on the severe ulcerations that can occur from repeated xylazine exposure, withdrawal symptoms, and the interference xylazine can cause on successful treatment. The FDA continues to investigate the source of xylazine in the illicit drug supply. Health care professionals are strongly encouraged to report events in humans associated with xylazine exposure.
Posted 4/4/2023 (updated 3/27/2024)
The U.S. Food and Drug Administration (FDA) announced that the makers of Narcan, an opioid overdose treatment, have the agency’s approval to make the drug widely available over the counter (OTC). Narcan is the brand name of the drug naloxone, a fast-acting overdose reversal. Until now, availability varied by state – typically restricted to licensed health care providers, approved opioid overdose programs, and first responders. This is an important consideration for rural counties given that research shows that these areas are nearly three times more likely than metropolitan counties to be a low-dispensing county for naloxone.
Posted 5/26/2023 (updated 3/27/2024)
The U.S. Food and Drug Administration approved Brixadi (buprenorphine) extended-release injection for subcutaneous use (under the skin) to treat moderate to sever opioid use disorder (OUD). Buprenorphine is a safe and effective medication for OUD treatment.
Posted 7/31/2023 (updated 3/26/2024)
At the end of July 2023, the U.S. Food and Drug Administration approved a second over-the-counter naloxone nasal spray product, RiVive. The agency who received the approval to manufacture the product, Harm Reduction Therapeutics, does not yet have a timeline of availability and decision on pricing.
Posted 10/23/2023 (updated 3/27/2024)
The Reagan-Udall Foundation partnered with the Food and Drug Administration (FDA) for the "Mitigating Risks from Human Xylazine Exposure" virtual and in-person webinar that occurred early October 2023. This public meeting explored real-world experiences and scientific evidence on emerging data trends for human xylazine exposure and examined concrete strategies for drug development and clinical research that directly supports the mitigation and reduction of risks associated with human exposure to xylazine. The meeting materials, recordings, and slides are now available for viewing.